Sun Pharmaceutical Industries Ltd. We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 40 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and strong dermatology range. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 6th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, Sept. 2010). Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals.